Mirum Pharmaceuticals, Inc. (MIRM)
96.74
+0.44
(+0.45%)
USD |
NASDAQ |
Aug 24, 16:00
96.74
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Debt to Equity Ratio : -73.21 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -73.21 |
| March 31, 2026 | 1.335 |
| December 31, 2025 | 1.015 |
| September 30, 2025 | 1.092 |
| June 30, 2025 | 1.250 |
| March 31, 2025 | 1.360 |
| December 31, 2024 | 1.408 |
| September 30, 2024 | 1.369 |
| June 30, 2024 | 1.382 |
| March 31, 2024 | 1.311 |
| December 31, 2023 | 1.239 |
| September 30, 2023 | 1.144 |
| June 30, 2023 | 3.916 |
| March 31, 2023 | 1.018 |
| December 31, 2022 | 1.004 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.8276 |
| June 30, 2022 | 1.247 |
| March 31, 2022 | 1.243 |
| December 31, 2021 | 1.102 |
| September 30, 2021 | 2.288 |
| June 30, 2021 | 1.290 |
| March 31, 2021 | 0.4031 |
| December 31, 2020 | 0.2958 |
| September 30, 2020 | 0.0283 |
| June 30, 2020 | 0.0255 |
| March 31, 2020 | 0.0231 |
| December 31, 2019 | 0.028 |
| September 30, 2019 | 0.01 |
| June 30, 2019 | 0.0159 |
| March 31, 2019 | 0.0293 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Incyte Corp. | 0.006 |
| Insmed, Inc. | 0.9865 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| BioMarin Pharmaceutical, Inc. | 0.6672 |
| Ionis Pharmaceuticals, Inc. | 4.978 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.045B |
| Total Liabilities (Quarterly) | 1.055B |
| Shareholders Equity (Quarterly) | -10.42M |
| Current Ratio | 2.856 |
| Net Debt Paydown Yield | -1.18% |